Health Condition 1: null- GIANT CELL TUMOR OF BONE
Conditions
Interventions
Intervention1: Surgery plus bisphosphonate: 15 patients. will recieve 5 mg iv zoledronic acid 3 doses at a interval of 1 month each before definative surgery
Control Intervention1: surgery alone: will
Sponsors
Department of Orthopaedics All India Institute Of Medical Science New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: All Patients of both genders and more than 12 years of age with primary and recurrent non-malignant Giant Cell Tumors of bones of extremities Patients with normal renal functions as measured by standard renal function test Patients giving informed consent for the study
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1.Patients with malignant and metastatic Giant Cell Tumors of bone 2.Patients not ready to give the consent for study 3.Patients with GCT of the axial skeleton 4.Patients with altered renal functions 5.Patients suffering from thyroid and parathyroid disorders 6.Patients with known allergies to bisphosphonates 7.Children less than 12 years of age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Apoptosis index using electron microscope at the time of suegeryTimepoint: 3 months i.e. at the time of surgery after completion of bisphosphonate therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| size of swelling pain by VAS score sclerosis on X ray Change in tumor volume on MRITimepoint: 3 months i.e. after completion of bisphosphonate therapy | — |
Countries
India
Contacts
Public ContactSiddharth Dubey
All India Institute Of Medical Sciences
Outcome results
None listed